Gain Therapeutics (GANX) Accumulated Expenses (2020 - 2026)

Gain Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $574244.0 for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 38.88% year-over-year to $574244.0; the TTM figure through Mar 2026 stood at $574244.0 (up 38.88% YoY), while the FY2025 annual figure was $518856.0, up 50.77% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $574244.0, up from $518856.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $2.1 million in Q3 2022, with the low at $344138.0 in Q4 2024.
• The 5-year median for Accumulated Expenses is $1.1 million (2022), against an average of $1.1 million.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses jumped 229.27% in 2022, then sank 62.49% in 2025.
• Gain Therapeutics' Accumulated Expenses stood at $1.1 million in 2022, then plunged by 32.86% to $726474.0 in 2023, then sank by 52.63% to $344138.0 in 2024, then jumped by 50.77% to $518856.0 in 2025, then rose by 10.68% to $574244.0 in 2026.
• Business Quant data shows GANX's Accumulated Expenses at $574244.0 in Q1 2026, $518856.0 in Q4 2025, and $1.0 million in Q3 2025.